Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis .
Autologous Bone Marrow-Derived Chondrocytes for Patients with Knee Osteoarthritis: A Randomized Controlled Trial.
Adv Orthop. 2021 Nov 20;2021: 2146722.Sixty patients aged 45-70 years old with knee osteoarthritis were randomized to receive a single intra-articular injection of autologous bone marrow-derived chondrocytes (n=30) or physical therapy and nonsteroidal anti-inflammatory drugs (NSAIDs). Outcomes of interest included pain on a Visual Analog Scale (VAS) with and without movement, the Modified Knee Society Score-Short Form (KSSSF), Activities of Daily Living (ADL) score, and quality of life score. Outcomes were assessed at 3, 12 and 24 months. Results demonstrated significantly favourable scores in the injection group in all outcomes, at all time-points.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
